Editorial comment on: low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in …

T Prayer-Galetti - European urology, 2007 - pubmed.ncbi.nlm.nih.gov
Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive
prostate cancer risk: an explanation for the adverse effects observed in chemoprevention …
被引用次数：1 相关文章

[引用][C] Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed …

T Prayer-Galetti - European Urology, 2007 - europepmc.org
Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive
prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials …

[引用][C] Editorial Comment on: Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects …

T Prayer-Galetti - European Urology, 2007 - infona.pl
Editorial Comment on: Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive
Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention …

[引用][C] Editorial Comment on: Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects …

T Prayer-Galetti - European Urology, 2007 - Elsevier